1-2 of 2
James P. Ohr
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit

Marco A. Mascarella, Tolani F. Olonisakin, Purva Rumde, Varun Vendra, Melonie A. Nance, Seungwon Kim, Mark W. Kubik, Shaum S. Sridharan, Robert L. Ferris, Moon J. Fenton, Daniel R. Clayburgh, James P. Ohr, Sonali C. Joyce, Malabika Sen, James G. Herman, Jennifer R. Grandis, Dan P. Zandberg, Umamaheswar Duvvuri
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 723–730.
https://doi.org/10.1158/1078-0432.CCR-22-1768
Published: 16 February 2023
View article titled, Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
Open the PDF for Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Bonnie S. Glisson, Rom S. Leidner, Robert L. Ferris, John Powderly, Naiyer A. Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James P. Ohr, Jennifer Burton, Yanan Zheng, Steven Eck, Matthew Gribbin, Katie Streicher, Danielle M. Townsley, Sandip Pravin Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5358–5367.
https://doi.org/10.1158/1078-0432.CCR-19-3070
Published: 15 October 2020
View article titled, Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data